ANNEX 7. Summary of Declared Interests

Participants	Declared interests	Declared amount	Level of participation
Isabelle Andrieux-Meyer	<i>Personal</i> : None <i>Institutional</i> : Employer (MSF) has received a UNITAID grant HIV-HCV grant to the value of 14 Million USD (current).	US\$14 million	Full
Lara Tavoschi	<i>Personal:</i> None <i>Institutional:</i> Participation in the meeting covered by ECDC The outcomes of the meeting will substantially impact ECDC's work on the subject.		Full
Manal El-Sayed	Personal: Travel support from MSD and Roche Institutional: None	Not declared	Full
Charles Gore	<i>Personal</i> : None <i>Institutional</i> : President of World Hepatitis Alliance that receives grants and other support from BMS, Boehringer Ingelheim, Janssen, Roche, Roche diagnostics, Merck, GSK, Gilead, AbbVie, Abbott, Achillion, Bayer, Novartis	not declared; but all the funding for the organization comes from these firms	Full
Richard Njouom	Personal: None Institutional: None		Full
Margaret Hellard (Chair)	<i>Persona</i> l: Research support from Gilead and Abbvie to support an investigator initiated independent research study. Provided expert opinion to Australian Parliamentary committee on hepatitis. <i>Institutional</i> : None	3.5 million plus drugs (research support was not for income)	Full
Niklas Luhmann	Personal: None Institutional: None		Full
Teri Roberts	<i>Personal</i> : None <i>Institutional</i> : None		Full
Jacinto Amandua	Personal: None Institutional: None		Full
John Parry	Personal: Expert advisor on other WHO panels (diagnostics and testing technologies) Institutional: Past research on DBS testing supported by Gilead (no longer current, study complete).	£30,000 (no longer current)	Full
Khwairakpam Giten Singh	Personal: None Institutional: None		Full

Roger Chou (methodologist)	Personal: None Institutional: None	Full
Michael Ninburg	Personal: None Institutional: None	Full
Trevor Peter	<i>Personal</i> : None <i>Institutional</i> : None	Full